The study showed that the therapy was able to help clear all signs of tumor in patients compared to neo-adjuvant placebo plus chemotherapy. The company said based on recommendation for the data monitoring committee, the study would continue without any changes to evaluate the second main goal of achieving statistically significant timeframe a patient remains free of any complication.
